Inmagene’s anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study
Article Date
August 18, 2023
This article is featured on another website.
Go to article
September 23, 2026
Chime Biologics and Magic Mirror Biotech Enter Strategic Partnership to Advance AI-Enabled Intelligent Manufacturing Across the Biologics Lifecycle
September 23, 2026